Get started
uniQure N.V.uniQure N.V.uniQure N.V.

uniQure N.V.

No trades
OverviewFinancialsNewsDocumentsIdeasMindsTechnicalsForecastsSeasonalsOptionsETFs

Chart


Full chart

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.38 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−4.39 USD
Net income (FY)
‪−239.56 M‬ USD
Revenue (FY)
‪27.12 M‬ USD
Shares float
‪56.79 M‬
Beta (1Y)
0.90

Employees


Employees (FY)
209
Change (1Y)
−271 −56.46%
Revenue / Employee (1Y)
‪129.76 K‬ USD
Net income / Employee (1Y)
‪−1.15 M‬ USD

About uniQure N.V.


Sector
Health Technology
Industry
Biotechnology
CEO
Matthew C. Kapusta
Website
uniqure.com
Headquarters
Amsterdam
Founded
2012
IPO date
Feb 5, 2014
IPO offer price
17.00 USD
Identifiers
2
ISIN NL0010696654
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

Check out other big names from the same industry as QURE.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs holding the stock


XBI
State Street SPDR S&P Biotech ETF
Weight
0.73%
Market value
‪62.49 M‬
USD
IBB
iShares Biotechnology ETF
Weight
0.10%
Market value
‪9.04 M‬
USD
SCHA
Schwab U.S. Small-Cap ETF
Weight
0.03%
Market value
‪6.48 M‬
USD
KOMP
State Street SPDR S&P Kensho New Economies Composite ETF
Weight
0.11%
Market value
‪2.91 M‬
USD
LABU
Direxion Daily S&P Biotech Bull 3X Shares
Weight
0.43%
Market value
‪2.71 M‬
USD
JGRO
JPMorgan Active Growth ETF
Weight
0.03%
Market value
‪2.41 M‬
USD
FRTY
Alger Mid Cap 40 ETF
Weight
0.96%
Market value
‪1.17 M‬
USD
BTEC
iShares NASDAQ US Biotechnology UCITS ETF
Weight
0.11%
Market value
‪1.02 M‬
USD
BTEE
iShares NASDAQ US Biotechnology UCITS ETF
Weight
0.11%
Market value
‪1.02 M‬
USD
LONG
CI Global Longevity Economy Fund
Weight
1.11%
Market value
‪529.13 K‬
USD
GNOM
Global X Genomics & Biotechnology ETF
Weight
0.97%
Market value
‪527.02 K‬
USD

Explore more ETFs 

Frequently Asked Questions


The current price of QURE is 22.93 USD — it has increased by 5.47% in the past 24 hours. Watch uniQure N.V. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange uniQure N.V. stocks are traded under the ticker QURE.
QURE stock has risen by 3.99% compared to the previous week, the month change is a −7.39% fall, over the last year uniQure N.V. has showed a 53.38% increase.
We've gathered analysts' opinions on uniQure N.V. future price: according to them, QURE price has a max estimate of 95.00 USD and a min estimate of 27.00 USD. Watch QURE chart and read a more detailed uniQure N.V. stock forecast: see what analysts think of uniQure N.V. and suggest that you do with its stocks.
QURE reached its all-time high on Jun 20, 2019 with the price of 82.49 USD, and its all-time low was 3.73 USD and was reached on Jul 5, 2024. View more price dynamics on QURE chart.
See other stocks reaching their highest and lowest prices.
QURE stock is 6.24% volatile and has beta coefficient of 0.90. Track uniQure N.V. stock price on the chart and check out the list of the most volatile stocks — is uniQure N.V. there?
Today uniQure N.V. has the market capitalization of ‪1.34 B‬, it has increased by 3.27% over the last week.
Yes, you can track uniQure N.V. financials in yearly and quarterly reports right on TradingView.
uniQure N.V. is going to release the next earnings report on Mar 2, 2026. Keep track of upcoming events with our Earnings Calendar.
QURE earnings for the last quarter are −1.38 USD per share, whereas the estimation was −0.90 USD resulting in a −52.86% surprise. The estimated earnings for the next quarter are −0.92 USD per share. See more details about uniQure N.V. earnings.
uniQure N.V. revenue for the last quarter amounts to ‪3.70 M‬ USD, despite the estimated figure of ‪5.79 M‬ USD. In the next quarter, revenue is expected to reach ‪5.32 M‬ USD.
QURE net income for the last quarter is ‪−80.53 M‬ USD, while the quarter before that showed ‪−37.72 M‬ USD of net income which accounts for −113.50% change. Track more uniQure N.V. financial stats to get the full picture.
No, QURE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 22, 2026, the company has 209 employees. See our rating of the largest employees — is uniQure N.V. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. uniQure N.V. EBITDA is ‪−176.91 M‬ USD, and current EBITDA margin is −632.89%. See more stats in uniQure N.V. financial statements.
Like other stocks, QURE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade uniQure N.V. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So uniQure N.V. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating uniQure N.V. stock shows the buy signal. See more of uniQure N.V. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.